{"id":"b22821c6b741","type":"article","url":"https://hartvaat.nl/2026/11/12/verhoogd-methylmalonaat-correleert-met-vaatverkalking-bij-chronische-nierziekte/","title":"Verhoogd methylmalonaat correleert met vaatverkalking bij chronische nierziekte","title_en":"Association between methylmalonic acid and vascular calcification in patients with chronic kidney disease: an observational study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"International urology and nephrology","doi":"10.1007/s11255-026-05432-6","source_url":"https://doi.org/10.1007/s11255-026-05432-6","authors":["Xinyue Yang","Jingjing Jin","Meijuan Cheng","Yaqin Kang","Shenglei Zhang","Yaling Bai","Jinsheng Xu"],"significance":5,"published":"2026-11-19","source_date":"2026-11-12","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This observational study evaluated the association between serum methylmalonic acid (MMA) and vascular calcification in patients with stage 5 chronic kidney disease. Among 144 participants, 82.6% had vascular calcification; after multivariable adjustment, each 1 ng/mL increase in MMA was associated with a 13% higher odds of more severe calcification (OR=1.13; 95% CI 1.05–1.22; p=0.001), a finding replicated in the NHANES validation cohort (n=326). Elevated MMA may serve as a novel biomarker to identify CKD patients at higher risk for vascular calcification, aiding cardiovascular risk stratification and monitoring in nephrology and cardiology practice.","created":"2026-11-13T02:15:40Z","updated":"2026-11-13T02:15:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit observatieonderzoek onderzocht de relatie tussen serummethylmalonaat (MMA) en vaatverkalking bij patiënten met chronische nierziekte (CKD) stadium 5. Van de 144 deelnemers had 82,6% vaatverkalking; na correctie voor covariaten ging elke toename van 1 ng/mL MMA gepaard met een 13% hogere kans op een ernstiger calcificatiegraad (OR=1,13; 95% BI 1,05-1,22; p=0,001). De associatie werd bevestigd in de externe NHANES-cohort (n=326). MMA kan als potentiële risicomarker dienen om CKD-patiënten in kaart te brengen voor vaatverkalking, wat relevant is voor het stratificeren van cardiovasculair risico en follow-up.","abstract_original":"BACKGROUND: Methylmalonic acid (MMA) has been regarded as a risk factor for cardiovascular diseases. However, the association between MMA and vascular calcification (VC) in patients with chronic kidney disease (CKD) remains unclear. METHODS: Patients with CKD stage 5 were included and classified into either non-VC, mild VC, or severe VC groups. Restricted cubic splines (RCS) analysis and ordinal logistic regression were performed to examine the relationship between MMA and VC. Moreover, independent external validation was performed based on the NHANES dataset. RESULTS: A total of 144 patients with CKD were involved, among whom 82.6% had VC. Compared with individuals without VC, serum MMA levels were elevated among those with VC, especially in the severe VC group (P=0.012). RCS analysis revealed an approximately positive linear relationship between MMA and VC (P-nonlinear=0.11). After adjusting for all covariates, each 1 ng/mL increase in serum MMA was associated with 13% higher odds of being in a more severe VC category (OR=1.13, 95%: 1.05-1.22, P=0.001). Additionally, subgroup analyses indicated that the direction of association between MMA and VC was consistent across different age, gender, hypertension, and diabetes groups (P for interaction was 0.77, 0.65, 0.83, and 0.34, respectively). Finally, results were confirmed in the NHANES cohort (n=326). CONCLUSION: High levels of MMA have a positive association with the risk of VC, particularly severe VC. This study may provide a novel risk marker for VC in patients with CKD."}